© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > CC-92480
<< Back to March
CRBN-based selective IKZF1/3 degrader
oral efficacy in lenalidomide-resist. xenograft
from phenotypic screen and optimization
J. Med. Chem., Mar. 4, 2020
Celgene, San Diego, CA
CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)
Unlock this content with a Premium membership to read it now.